International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin's lymphomas: Report of the jury

Journal of Clinical Oncology

Volumn 17, Issue 1, 1999, Pages 423-429

  Shipp, Margaret A ^a   Abeloff, M D ^b   Antman, K H ^b   Carroll, G ^b   Hagenbeek, A ^b   Loeffler, M ^b   Montserrat, E ^b   Radford, J A ^b   Salles, G ^b   Schmitz, N ^b   Symann, M ^b   Armitage, J O ^b   Philip, T ^b   Coiffier, B ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; MELPHALAN; METHOTREXATE; PREDNISONE; VINCRISTINE;

ALLOTRANSPLANTATION; BONE MARROW PURGING; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL TRIAL; DRUG MEGADOSE; DRUG RESISTANCE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; NONHODGKIN LYMPHOMA; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW;

EID: 0032951328     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.1.423     Document Type: Review

References (32)

1. Coiffier B, Philip T, Burnett A, et al: Consensus conference on intensive chemotherapy plus hematopoietic stem cell transplantation in malignancies: Lyon, June 4-6, 1993. Ann Oncol 5:19-23, 1994
2. Stevens A, Raftery J (eds): Health Care Needs Assessment: The Epidemiologically Based Needs Assessment Reviews. Oxford, UK, Radcliffe Medical Press, 1994, ch 1, p 15
3. Philip T, Guglielmi C, Hagenbeek A, et al: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333:1540-1545, 1995
4. Vose J: High-dose chemotherapy and hematopoietic stem cell transplantation for relapsed or refractory diffuse large-cell non-Hodgkin's lymphoma. Ann Oncol 9:S1-S3, 1998 (suppl 1)
5. Bosly A, Sonet A, Salles G, et al: Superiority of late over early intensification in relapsing/refractory aggressive non-Hodgkin's lymphoma: A randomized study from the GELA: LNH RP 93. Blood 90:594a. 1997 (suppl 1)
6. Philip T, Armitage JO, Spitzer G, et al: High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 316:1493-1498, 1987
7. Vose J, Rowlings P, Lazarus H, et al: Multivariate analysis of autotransplant for patients with aggressive non-Hodgkin's lymphoma failing primary induction therapy. Blood 90:594a, 1997 (suppl 1)
8. Perry A, Goldstone A: High-dose therapy for diffuse large-cell lymphoma in first remission. Ann Oncol 9:S9-S14, 1998 (suppl 1)
9. Haioun C, Lepage E, Gisselbrecht C, et al: Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: Updated results of the prospective study LNH87-2. J Clin Oncol 15:1131-1137, 1997
10. Santini G, Salvagno L, Leoni P, et al: VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: Results of a prospective randomized trial by the Non-Hodgkin's Lymphoma Cooperative Study Group. J Clin Oncol 16:2796-2802, 1998
11. Reyes F, Lepage E, Morel P, et al: Failure of first-line inductive high-dose chemotherapy (HDC) in poor-risk patients (PTS) with aggressive lymphoma: Updated results of the randomized LNH93-3 study. Blood 90:594a, 1997 (suppl 1)
12. Kaiser U, Uebelacker I, Havemann K on behalf of the German High Grade Lymphoma Study Group, Marburg, Germany: High dose chemotherapy with autologous stem cell transplantation in high grade NHL: First analysis of a randomized multicenter study. Bone Marrow Transplant 21:5177, 1998 (suppl 1)
13. Gianni A, Bregni M, Siena S, et al: High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 336:1290-1297, 1997
14. Haioun C, Lepage E, Gisselbrecht C, et al: Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: A study of 464 patients. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 12:2543-2551, 1994
15. Waits TM, Greco FA, Greer JP, et al: Effective therapy for poor-prognosis non-Hodgkin's lymphoma with 8 weeks of high-dose-intensity combination chemotherapy. J Clin Oncol 11:943-949, 1993
16. Shipp M, Neuberg D, Janicek M, et al: High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: A dose-finding pilot study. J Clin Oncol 13:2916-2923, 1995
17. Haioun C, Lepage E, Gisselbrecht C, et al: High-dose therapy followed by stem cell transplantation in partial response after first-line induction therapy for aggressive non-Hodgkin's lymphoma. Ann Oncol 9:S5-S8, 1998 (suppl 1)
18. Verdonck LF, van Putten WL, Hagenbeek A, et al: Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl J Med 332:1045-1051, 1995
19. Martelli M, Vignetti M, Zinzani P, et al: High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: A prospective random-ized Italian multicenter study. J Clin Oncol 14:534-542, 1996
20. Mounier N, Gisselbrecht C: Conditioning regimens before transplantation in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 9:S15-S21, 1998 (suppl 1)
21. Kessinger A: Consensus conference on high-dose therapy with hematopoietic stem cell transplantation in diffuse large-cell lymphoma: Type of cells, optimal mobilization of stem cells-positive and negative selection. Ann Oncol 9:S23-S30, 1998 (suppl 1)
22. Liberti G, Pearce R, Taghipour G, et al: Comparison of peripheral blood stem-cell and autologous bone marrow transplantation for lymphoma patients: A case-controlled analysis of the EBMT Registry data. Lymphoma Working Party of the EBMT. Ann Oncol 5:151-153, 1994 (suppl 2)
23. Schmitz N, Linch D, Dreger P, et al: Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 347:353-357, 1996
24. Hartmann O, Le Corroller A, Blaise D, et al: Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: Hematologic recovery and costs. Ann Intern Med 126:600-607, 1997
25. Vose J, Sharp J, Chan W, et al: High-dose chemotherapy (HDC) and autotransplant for non-Hodgkin's lymphoma (NHL): Randomized trial of peripheral blood (PSCT) versus bone marrow (ABMT) and evaluation of minimal residual disease (MRD). Proc Am Soc Clin Oncol 16:90a, 1997 (abstr)
26. Damiani D, Fanin R, Silvestri F, et al: Randomized trial of autologous filgrastim-primed bone marrow transplantation versus filgrastim-mobilized peripheral blood stem cell transplantation in lymphoma patients. Blood 90:36-42, 1997
27. Gribben J, Freedman A, Neuberg D, et al: Immunologic purging of marrow assessed by PCR before autologous bone marrow transplan-tation for B-cell lymphoma. N Engl J Med 325:1525-1533, 1991
28. Williams C, Goldstone A, Pearce R, et al: Purging of bone marrow in autologous bone marrow transplantation for non-Hodgkin's lymphoma: A case-matched comparison with unpurged cases by the European Blood and Marrow Transplant Lymphoma Registry. J Clin Oncol 14:2454-2464, 1996
29. Sharp J, Kessinger A, Mann S, et al: Outcome of high-dose therapy and autologous transplantation in non-Hodgkin's lymphoma based on the presence of tumor in the marrow or infused hematopoietic harvest. J Clin Oncol 14:214-219, 1996
30. Kessinger A, Anderson J, Bierman P, et al: Outcomes of patients with bone marrow metastases treated with high dose therapy and rescued with peripheral blood progenitor cells. Blood 90:232a, 1997 (suppl 1)
31. Kwak L: Tumor vaccination strategies combined with autologous peripheral stem cell transplantation. Ann Oncol 9:S41-S46, 1998 (suppl 1)
32. Slavin S, Nagler A: Immunotherapy in conjunction with autologous and allogeneic blood or marrow transplantation in lymphoma. Ann Oncol 9:S31-S39, 1998 (suppl 1)